Close

Dr Daniel Grint

BSc MSc PhD

Assistant Professor
of Medical Statistics & Epidemiology

Room
G12

LSHTM
Keppel Street
London
WC1E 7HT
United Kingdom

Tel.
x4818

Affiliations

Department of Infectious Disease Epidemiology
Faculty of Epidemiology and Population Health

Centres

Centre for Statistical Methodology
TB Centre

Teaching

I co-organise the distance learning module EPM304 (Advanced Statistical Methods in Epidemiology). I also teach on the in-house courses Statistics for Epidemiology and Population Health (STEPH), Statistical Methods in Epidemiology (SME) and Advanced Statistical Methods in Epidemiology (ASME).

Research

I am a member of the International Statistics & Epidemiology Group (ISEG) and have links with the Electronic Health Records (EHR) group. My research focuses on the design, implementation and analysis of randomised clinical trials, along with analysis of electronic health records.

I am the trial statistician on the RIFASHORT trial. This trial with sites in Botswana, Uganda, Guinea, Peru, Nepal, and Pakistan aims to assess the efficacy and saftey of 4-month high-dose rifampicin treatment regimens for TB, and will report in 2023.

I have experience serving as an independant statistician on the Data Safety and Monitoring Boards (DSMB) of trials of TB treatment.

I am also analysing electronic health record data from UK general practices to test hypotheses relating to COVID-19 and inform pandemic modelling studies.

Research Area
Clinical trials
Diagnostics
Infectious disease policy
Statistical methods
Electronic health records
Pharmacokinetics
Randomised controlled trials
Discipline
Epidemiology
Statistics
Disease and Health Conditions
HIV/AIDS
Infectious disease
Meningitis
Tuberculosis
Diabetes
Hepatitis
Region
European Union
Latin America & Caribbean (all income levels)
Sub-Saharan Africa (all income levels)

Selected Publications

High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial.
Cresswell FV; Meya DB; Kagimu E; Grint D; Te Brake L; Kasibante J; Martyn E; Rutakingirwa M; Quinn CM; Okirwoth M
2021
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England.
Grint DJ; Wing K; Houlihan C; Gibbs HP; Evans SJW; Williamson E; McDonald HI; Bhaskaran K; Evans D; Walker AJ
2021
Clinical infectious diseases
Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February.
Grint DJ; Wing K; Williamson E; McDonald HI; Bhaskaran K; Evans D; Evans SJ; Walker AJ; Hickman G; Nightingale E
2021
Eurosurveillance
UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records
Walker JL; Grint DJ; Strongman H; Eggo RM; Peppa M; Minassian C; Mansfield KE; Rentsch CT; Douglas IJ; Mathur R
2020
MedRxiv
Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study.
Gupta-Wright A; Corbett EL; Wilson D; van Oosterhout JJ; Dheda K; Huerga H; Peter J; Bonnet M; Alufandika-Moyo M; Grint D
2019
PLoS medicine
Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa.
Grint D; Alisjhabana B; Ugarte-Gil C; Riza A-L; Walzl G; Pearson F; Ruslami R; Moore DAJ; Ioana M; McAllister S
2018
Bulletin of the World Health Organization
Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial.
Gupta-Wright A; Corbett EL; van Oosterhout JJ; Wilson D; Grint D; Alufandika-Moyo M; Peters JA; Chiume L; Flach C; Lawn SD
2018
LANCET
Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals.
Grint D; Peters L; Rockstroh JK; Rakmanova A; Trofimova T; Lacombe K; Karpov I; Galli M; Domingo P; Kirk O
2015
AIDS (London, England)
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.
Grint D; Peters L; Schwarze-Zander C; Beniowski M; Pradier C; Battegay M; Jevtovic D; Soriano V; Lundgren JD; Rockstroh JK
2013
HIV medicine
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.
Peters L; Grint D; Lundgren JD; Rockstroh JK; Soriano V; Reiss P; Grzeszczuk A; Sambatakou H; Mocroft A; Kirk O
2012
AIDS (London, England)
See more Publications